Introduction {#s1}
============

Protein Kinase A (PKA) is a cyclic AMP (cAMP)-dependent Ser/Thr kinase involved in regulating a multitude of biological processes including cell growth and division, cell differentiation, as well as metabolism and immune responsiveness [@pone.0034838-Skalhegg1]. In its inactive state, PKA exists as a tetrameric holoenzyme consisting of two regulatory (R) and two catalytic (C) subunits. Four different genes, *PRKAR1A*, *PRKAR1B*, *PRKAR2A*, and *PRKAR2B*, encode the R subunit proteins RIα, RIβ, RIIα, and RIIβ, respectively, with several splice variants of the RIα and RIIα subunits [@pone.0034838-Oyen1], [@pone.0034838-Solberg1]. Two principal genes, *PRKACA* and *PRKACB*, encode the C subunits Cα and Cβ, respectively. Also, *PRKX* and the retroposons *PRKY* and *PRKACG* are identified as PKA C subunit genes. While no protein products for *PRKY* and *PRKACG* have been identified, *PRKX* is translated into a protein kinase which is inhibited by the R subunit in a cAMP-sensitive manner [@pone.0034838-Beebe1]--[@pone.0034838-Zimmermann1]. Both the *PRKACA* and *PRKACB* genes encode several protein products. Alternative use of two exons upstream of exon 2 in the *PRKACA* gene gives rise to two Cα variants with different N-termini. These proteins are designated Cα1 and Cα2 [@pone.0034838-Desseyn1]--[@pone.0034838-Uhler1]. In the case of the *PRKACB* gene, several exons 5′ of exon 2 are encoding a number of Cβ splice variants designated Cβ1, Cβ2, Cβ3, and Cβ4 [@pone.0034838-Guthrie1], [@pone.0034838-Wiemann1], as well as a number of Cβ3 and Cβ4 forms that contain N-terminal inserts from exons designated a, b, and c [@pone.0034838-Orstavik1], [@pone.0034838-Kvissel1]. In the brain and nervous tissues of higher primates, a range of C variants lacking exon 4 encoded sequences are also identified [@pone.0034838-Larsen1].

The two major groups of the R subunits RI and RII form two types of the PKA holoenzymes termed PKA type I and PKA type II, respectively. The C subunits are the catalytically active components, and they become activated after dissociation from the R subunits in a cAMP-dependent manner. For specificity in the cAMP-PKA signaling pathway, the PKA holoenzymes can be located to specific subcellular structures via A Kinase Anchoring Proteins (AKAPs). AKAPs typically bind RII subunits with high affinity [@pone.0034838-Desseyn1], [@pone.0034838-Colledge1]--[@pone.0034838-Tasken1]. In contrast, PKA type I holoenzymes tend to locate to the soluble fraction of the cell but can bind to dual- and RI-specific AKAPs [@pone.0034838-Tasken1]. Both the C and R subunits are differentially expressed in various tissues. Whereas Cα1 is ubiquitously expressed, Cα2 is exclusively found in sperm cells [@pone.0034838-Desseyn1]--[@pone.0034838-SanAgustin1]. For the Cβ variants, Cβ1 is ubiquitously expressed, while the other Cβ variants are more specifically expressed in certain tissues, such as lymphoid and neuronal tissues [@pone.0034838-Orstavik1], [@pone.0034838-Kvissel1].

Cα1 is the principal source of PKA activity in most tissues [@pone.0034838-Uhler1] and was the first protein kinase to be subjected to crystallization and 3D structure determination [@pone.0034838-Knighton1]. The Cα1 structure reveals a large C terminal lobe (C-lobe or large lobe) and a smaller N terminal lobe (N-lobe or small lobe). The large lobe is mainly composed of α-helices, and is involved in R subunit and substrate binding. It contains a number of residues involved in catalysis. The small lobe is mostly composed of β-strands and contains an ATP binding site. Between the large and small lobe is the active site cleft. The small and large lobes, as well as the active site, are known as the catalytic core and are encoded by residues 40--300 in PKA Cα1. The amino acid sequence and 3D structure of the catalytic core are conserved among all protein kinases. The catalytic core may, in addition to ATP, bind two Mg^2+^ ions that are critical for catalysis [@pone.0034838-Knighton1]. The two Mg^2+^ ions are designated activating and inhibitory Mg^2+^, or Mg1 and Mg2, respectively [@pone.0034838-Khavrutskii1]. The binding affinity for Mg1 is higher than for Mg2 in the presence of ATP, while binding of Mg2 is believed to stabilize the protein, but also to inhibit catalysis [@pone.0034838-Khavrutskii1]--[@pone.0034838-Adams1]. Mg^2+^ is also essential for high-affinity binding to inhibitors PKI and RIα subunits [@pone.0034838-Zimmermann2]. For catalytic activity, Cα has to be phosphorylated on residue Thr~197~, located in the activation loop of the large lobe. This phosphorylation affects the conformation of the conserved DFG (Asp~184~-Phe-Gly) motif in the active site [@pone.0034838-Taylor1]. In the active conformation, Asp~184~ of the DFG motif coordinates the three phosphates of ATP via the Mg^2+^ ions, positioning the γ-phosphate of ATP optimally for catalysis. This central role of Asp~184~ in catalysis depends on a conserved hydrogen bond between Asp~184~ and Gly~186~ backbone amide group. This interaction orients Asp~184~ perfectly for coordination of the Mg^2+^ ions and efficient ATP binding [@pone.0034838-Kornev1]. The Asp~184~-Gly~186~ hydrogen bond is only established after phosphorylation of Thr~197~, which causes a twist of the peptide bond between Phe~185~ and Gly~186~. In this way phosphorylation of Thr~197~ serves as a regulatory mechanism for the activation of the C subunit. The Local Spatial Pattern (LSP) alignment method, developed by Kornev et al [@pone.0034838-Kornev1], has revealed two conserved spatial motifs in eukaryotic protein kinases. These are two hydrophobic structures called the Catalytic (C-) and Regulatory (R-) spines that have to be established in order for the kinase to become catalytically active. The C-spine is completed when the adenine nucleobase of ATP interacts with the active site. For the R-spine to be established, Thr~197~ in the activation loop has to be phosphorylated. Evaluation of the C- and R-spines is a helpful way of predicting whether a kinase has a catalytically active or inactive conformation.

Despite its central role in a multitude of processes in the body, few diseases have been linked to defects or alterations in the PKA subunit genes or proteins. Germline mutations leading to premature stop codons in *PRKAR1A* have been identified in patients with Carney complex, a multiple neoplasia syndrome with skin pigmentations, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas [@pone.0034838-Boikos1], [@pone.0034838-Kirschner1]. To the best of our knowledge, no diseases have been linked to defects in any of the C subunit genes. Nevertheless, studies on mice that are homozygote knockout (KO) for the *PRKACA* gene reveal a severe phenotype. The majority of the Cα^−/−^ mice die at birth or during the early postnatal period [@pone.0034838-Skalhegg2]. The offspring that survive beyond 2 months (\< 11%, [@pone.0034838-Funderud1]), all show reduced growth, and the few males, but not females, that reach puberty are all 100% infertile [@pone.0034838-Skalhegg2], [@pone.0034838-Nolan1]. Furthermore, mice with reduced PKA C gene transcription by only expressing one functional C subunit allele of Cα or Cβ, show reduced PKA activity and neural tube defects [@pone.0034838-Huang1].

Due to the severe phenotype of Cα KO mice we searched for mutations in the human *PRKACA* gene by genomic sequencing of 498 subjects. We identified two nonsynonymous point mutations in the *PRKACA* gene that result in amino acid switches in the Cα1 protein at residues 45 and 109. In addition, we searched for previously described nonsynonymous mutations in various human genomic DNA databases, and selected two of these, giving amino acid switches at residues 186 and 263, for further studies. These four mutations were introduced to Cα1- and Cα2-encoding plasmids and the proteins were expressed and analyzed with respect to kinase activities and R subunit binding *in vitro* and *in vivo*. Mutation of residues 109 and 186 were associated with significantly reduced and totally abrogated kinase activity, respectively. In addition, mutation of residue 186 rendered Cα incapable of forming PKA type I holoenzymes.

Materials and Methods {#s2}
=====================

Analysis of Mutations {#s2a}
---------------------

The *PRKACA* gene from 498 Norwegian donors deriving from three different control groups [@pone.0034838-Heimdal1], [@pone.0034838-Olsen1] was sequenced and analyzed for point mutations by Lark Technologies (Takeley, UK). Leukocyte DNA was isolated from thawed blood containing ethylenediaminetetraacetic acid. Using the Applied Biosystems 340A Nucleic Acid Extractor, DNA was extracted with chloroform/phenol followed by ethanol precipitation. Exons 2--10 of *PRKACA* were sequenced using the primers listed in [table 1](#pone-0034838-t001){ref-type="table"}.

10.1371/journal.pone.0034838.t001

###### Primers used for sequencing of *PRKACA* exons 2 to 10.

![](pone.0034838.t001){#pone-0034838-t001-1}

  Sequencing of exon no.                   Primers
  ------------------------ ----------------------------------------
  2                          Forward: 5′-AGGCTCTGGGTTGGAACTGC-3′
  2                          Reverse: 5′-CTGGCATTGGGCAGTCAGGT-3′
  3                          Forward: 5′-GCCTTAAGGAATGTGCCCTC-3′
  3                          Reverse: 5′-TGGCGAAAACCCATCTCTAC-3′
  4                          Forward: 5′-CCACGGCTCTGACCTCTGTG-3′
  4                          Reverse: 5′-GATGTTACTGAGGTTGGGTG-3′
  5                          Forward: 5′-CTCAAGCTCCCAGAGCAAGG-3′
  5                          Reverse: 5′-TACTGGTGAGAACCACCGTG-3′
  6--8                       Forward: 5′-AATGCAGCCACATTGTTGAG-3′
  6--8                       Reverse: 5′-TTGAGGTGTTGGCCTCAGTG-3′
  9                          Forward: 5′-ACGTAGTGAGACCCTGTCTC-3′
  9                         Reverse: 5′-CGAAACTCTTAATGTAGCAACTC-3′
  10                         Forward: 5′-AGTGGTTTGCCACAACTGAC-3′
  10                         Reverse: 5′-AGCTGGTGTTTCTGTCCCTC-3′

A search for mutations in the *PRKACA* gene was also performed in the following public databases: NCBÍs dbSNP [@pone.0034838-Sherry1], [@pone.0034838-Sayers1], Ensembl [@pone.0034838-Flicek1], and SNPper [@pone.0034838-Riva1].

Generation of Plasmids {#s2b}
----------------------

The pDONR201-Cα1~WT~ vector has previously been described [@pone.0034838-Orstavik2] and was used to make plasmids containing Cα1~Mut~ using QuikChange® II Site-Directed Mutagenesis Kit (Stratagene, cat. no. 200524) according to the manufacturer's protocol. The pDONR201-Cα1 variants were transferred to the eukaryotic expression vector pEF-DEST51 by the LR recombination reaction (Invitrogen, cat. no. 11791--019) according to the manufacturer's protocol.

Cα1~WT~ and Cα2~WT~ prokaryotic expression vectors are previously described [@pone.0034838-Vetter1]. Using QuikChange^TM^ Site-Directed Mutagenesis Kit (Stratagene, cat. no. 200518), Cα2~WT~ was mutated into Cα2~Gly186Val~.

Cα1 was cloned into the mammalian expression vector pGFP^2^-C3 (Perkin Elmer) as previously described [@pone.0034838-Prinz1], creating the BRET sensor construct GFP-Cα1~WT~. Using Quikchange® II Site-Directed Mutagenesis Kit, GFP-Cα1~WT~ was mutated into GFP-Cα1~Mut~, according to the manufacturer's protocol. RIα-Rluc and RIIα-Rluc constructs have previously been described [@pone.0034838-Prinz1].

For all mutagenesis reactions, the PCR reaction mixture was initially heated to 95°C for 30 s, followed by 16 cycles of 95°C for 30 s, 55°C for 1 min and 68°C for 7 min, before final elongation at 68°C for 2 min. Primers are listed in [table 2](#pone-0034838-t002){ref-type="table"}. All plasmids were verified by sequencing (Eurofins MWG Operon).

10.1371/journal.pone.0034838.t002

###### Primers for mutagenesis (mutated nucleotide in bold).

![](pone.0034838.t002){#pone-0034838-t002-2}

  Desired mutation                           Primers
  ------------------ --------------------------------------------------------
  Arg45Gln            Forward: 5′- CTTGGATCAGTTTGAAC**A**AATCAAGACCCTCGGC-3′
  Arg45Gln            Reverse: 5′-GCCGAGGGTCTTGATT**T**GTTCAAACTGATCCAAG-3′
  Ser109Pro            Forward: 5′-CGTCAAACTCGAGTTC**C**CCTTCAAGGACAACTC-3′
  Ser109Pro            Reverse: 5′-GAGTTGTCCTTGAAGG**G**GAACTCGAGTTTGACG-3′
  Gly186Val              Forward: 5′-GGTGACAGACTTCG**T**TTTCGCCAAGCGCG-3′
  Gly186Val              Reverse: 5′-CGCGCTTGGCGAAA**A**CGAAGTCTGTCACC-3′
  Ser263Cys             Forward: 5′-CCTTCCCACTTCAGCT**G**TGACTTGAAGGACC-3′
  Ser263Cys             Reverse: 5′-GGTCCTTCAAGTCA**C**AGCTGAAGTGGGAAGG-3′

Purification of Proteins {#s2c}
------------------------

Cα1~WT~ and Cα2~WT~ were purified by affinity chromatography using PKI-peptide Affi-Gel, as previously described [@pone.0034838-Vetter1]. Cα2~Gly186Val~ was purified using a modified method described by Hemmer et al [@pone.0034838-Hemmer1]. Briefly, BL21(DE3) cells transformed with either Cα2~Gly186Val~ or His-tagged RIIα~Gly337Glu~ (provided by Antje Badel, University of Kassel, Germany) were cultured and protein expression induced with IPTG. After centrifugation, the bacterial pellets were resuspended and lysed, and the lysates were mixed in equimolar amounts forming PKA holoenzymes. The holoenzymes were then coupled to a Ni^2+^-resin binding the His-tagged R subunits. Following washing with 50 mM NaH~2~PO~4~ (pH 8.0), 5 mM β-mercaptoethanol, and 25 mM KCl, Cα2~Gly186Val~ was eluted with the same buffer supplemented with 10 mM cAMP.

Cell Cultures and Transfection Methods {#s2d}
--------------------------------------

HEK 293T cells (ATTC, cat. no. CRL-11268) were cultured at 37°C in humidified air with 5% CO~2~ in RPMI 1640 (Sigma-Aldrich, cat. no. R0883) supplemented with 10% fetal bovine serum (Sigma-Aldrich, cat. no. F7524), 1% non-essential amino acids (GibcoBRL, cat. no. 11140--035), 1% L-glutamine (Sigma-Aldrich, cat. no. G7513), sodium pyruvate (GibcoBRL, cat. no. 11360--039) and 1% Penicillin-Streptomycin solution (Sigma-Aldrich, cat. no. P4458). The 293T cells were transfected with Lipofectamine 2000 (Invitrogen, cat. no. 11668--019) according to the manufacturer's instructions.

COS-7 cells (ATCC, cat. no. CRL-1651) were cultivated in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich), with 10% (v/v) fetal calf serum (FCSgold, PAA, Coelbe, Germany) at 37°C and 5% CO~2~. Cells were split in a 1∶3 ratio every 3--4 days and transfected using PEi (Polysciences, 25 kDa linear polyethylenimine) [@pone.0034838-Schirrmann1]. Cells were transfected as previously described [@pone.0034838-Prinz1]. Briefly, 2×10^4^ COS-7 cells were seeded in each well of a 96-well microplate (Nunclon Surface, cat. no. 136101). After 24 h, cells were transfected with plasmid DNA (0,2 µg per well) using PEi.

Phosphotransferase Assay {#s2e}
------------------------

20 h post transfection, the HEK 293T cells were harvested and washed 3 x in phosphate buffered saline, then lysed in a potassium-phosphate buffer (5 mM K~2~HPO~4~, 1 mM EDTA, 250 mM sucrose and 0.5% Triton X-100, 1 mM phenylmethanesulfonyl fluoride, 1 mM Na~3~VO~4~ and protease inhibitor cocktail (Sigma-Aldrich, cat. no. P8340)) by vortexing and 20 min on ice. Debris was pelleted by centrifugation at 16 000 g for 15 min at 4°C. After Bradford protein determination (Bio-Rad, cat. no. 500--0006), all samples were adjusted to equal concentrations. Phosphotransferase activities of lysates from Cα1~WT~, Cα1~Mut~, and mock transfected cells were determined by the phosphotransferase assay described by Witt and Roskoski [@pone.0034838-Witt1], [@pone.0034838-Kemp1]. Briefly, phosphotransferase activity against the PKA-specific substrate Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly, Sigma-Aldrich) was measured in a reaction mixture (14.3 mM Mg-acetate, 143 µM ATP, 7.5 µCi/mL γ^−32^P-ATP (PerkinElmer), 50 mM Tris-HCl, pH 7.4) in the presence or absence of cAMP or PKI. After incubation at 30°C for 9 min, the reactions were stopped by spotting onto p81 phosphocellulose papers followed by 4 × 15 min washing in 75 mM phosphorous acid. The filter papers were washed in 96% ethanol for 10 min and air dryed for approximately 1 h. Phosphotransferase activity was measured by liquid scintillation in 3 ml Opti-fluor (Packard BioScience, PerkinElmer). All experiments were repeated at least three times.

BRET Assay {#s2f}
----------

48 h post transfection cells were washed with 1 × PBS and BRET read-out was performed by addition of 5 µM of the luciferase substrate coelenterazine 400 a (Biotrend, Cologne, Germany). After simultaneous detection of RLuc (410 nm) and GFP^2^ (515 nm) emission by a multi-label reader (POLARstar, Omega, BMG Labtech GmbH, Ortenberg, Germany) the ratiometric BRET signal was calculated as followed \[emission~515\ nm~ - (not transfected) COS-7 cells~515\ nm~\]/\[emission~410\ nm~- (not transfected) COS-7 cells~410\ nm~\] using the GraphPad Prism 4 software (La Jolla, CA, USA). Experiments were performed both in absence and presence of 50 µM forskolin (fsk) and 100 µM 3-isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich). All experiments were repeated at least three times.

Immunoblotting {#s2g}
--------------

Samples used in phosphotransferase assays were evaluated for C subunit expression. Protein concentrations of each sample within an assay were adjusted to the same levels, as described above. Proteins were separated by SDS-PAGE and transferred to PVDF membranes. The membranes were blocked by drying and rehydrated in methanol before incubation with primary antibody Purified Mouse Anti-PKA \[C\] (1∶250 dilution, BD Transduction Laboratories, cat. no. 610981) for 1 h, followed by washing with TBST. After 30 min incubation with secondary antibody HRP conjugated goat anti-mouse (1∶2000 dilution, ICN Biomed, cat. no. 55563) and washing, proteins were detected by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA) and the Syngene G:BOX imaging system.

Expression of endogenous C and GFP-C constructs in transfected COS-7 cells used for BRET assays were also assessed with immunoblotting. Proteins were detected similarly to the method described above, with the following modifications: blocking was performed with 5% milk powder for 1 h; primary antibody was rabbit anti-Cα (Santa Cruz, PKA cat (c-20) cat. no. SC-903) and secondary antibody anti-rabbit IgG (peroxidase-linked species-specific whole antibody (ECL) NA934, GE Healthcare, Freiburg, Germany).

Spectrophotometric Kinase Activity Assay {#s2h}
----------------------------------------

Kinetic activities of purified Cα2~WT~ and Cα2~Gly186Val~ were evaluated by the continuous enzyme-linked spectrophotometric method described by Cook et al. [@pone.0034838-Cook1]. Activities were reported in U/mg, defined as µmolmg^−1^min^−1^. All experiments were repeated at least three times.

Molecular Representation and Simulation {#s2i}
---------------------------------------

Selected motifs, including the DFG motif and it's interactions with ATP and divalent cations were presented and analyzed with PyMOL [@pone.0034838-Schrodinger1], using the experimental structure described by Thompson et al [@pone.0034838-Thompson1] (PDB identifier 3FJQ). Simulated mutagenesis in PyMOL was performed on Gly~186~ in the DFG motif. Relevant distances between the Gly~186~/Val~186~ residue and surrounding atoms were calculated.

Results {#s3}
=======

We performed two independent studies of the *PRKACA* gene; *1)* by sequencing genomic DNA from 498 Norwegian subjects and *2)* by a bioinformatics analysis of DNA sequences from various populations submitted to publicly available databases (see [Material and Methods](#s2){ref-type="sec"}). By the first approach, exons 2 through 10 of *PRKACA* were sequenced using exon-specific primers and genomic DNA extracted from leukocytes. In this way we detected five mutations in the *PRKACA* gene; one in each of exons 2, 3, 4, 5, and 8. Only two of the mutations translated into an amino acid switch. The corresponding nucleotides were located in exons 3 and 4, and are affecting Arg~45~ and Ser~109~ in the Cα1 sequence, while the three silent mutations were at Pro~33~, Gly~126~, and Pro~236~ ([Table 3](#pone-0034838-t003){ref-type="table"}, [Fig. 1A](#pone-0034838-g001){ref-type="fig"}). With the recent submission of a large amount of new mutations from several thousand individuals by exome and whole genome sequencing projects, four of these five mutations are now also present in dbSNP [@pone.0034838-Sherry1], [@pone.0034838-Sayers2]. Our study thus confirms the presence of the mutations referred to as rs56105247 (at Pro~33~), rs56085217 (Arg~45~), rs78098302 (Gly~126~), and rs137911238 (Pro~236~) in the Norwegian population.

10.1371/journal.pone.0034838.t003

###### Mutations in the *PRKACA* gene discovered by sequencing of 498 Norwegian subjects.

![](pone.0034838.t003){#pone-0034838-t003-3}

  Exon no.    Nucleotide (nt) no.   Amino acid (aa)   WT/mut nt   WT/mut aa   No. affected individuals                             Functional consequence prediction
  ---------- --------------------- ----------------- ----------- ----------- -------------------------- ----------------------------------------------------------------------------------------
  2                   102                Pro33           C/T       Silent                10                                                  Likely neutral
  3                   137                Arg45           G/A       Arg/Gln               1               Arg45 is highly conserved in metazoan Cα/Cβ homologs -- likely functional consequences
  4                   328               Ser109           T/C       Ser/Pro               2                             Ser109 in conserved in Cα, but not in Cβ -- effect unknown
  5                   381               Gly126           G/A       Silent                3                                                   Likely neutral
  8                   711               Pro236           G/A       Silent                1                                                   Likely neutral

Nucleotide enumeration is counted from the PKA Cα1 transcript start codon. Amino acid numbering is given for the mature protein with N-terminal Gly~1~ corresponding to codon 2. Sequence conservation is illustrated in Supplementary [Fig. S1](#pone.0034838.s001){ref-type="supplementary-material"}.

![Sequences of human wild type PKA Cα1/Cα2, location of point mutations, and activities of mutant proteins.\
**A.** The human Cα wild type and mutated amino acid sequence. The N-terminal methionine of Cα1 is removed post-translationally, and glycine residue 1 in mature Cα1 corresponds to codon 2. Alternating black and blue coloring shows the contribution of the eleven exons to the mature translated protein. The codons for Val~15~ and Ser~139~ (red) are encoded by nucleotides from neighboring exons. The *PRKACA* gene encodes two splice variants, Cα1 and Cα2 (UniProt [@pone.0034838-TheUniProt1] accession number P17612), which differs by alternative use of exons 1--1 or 1--2, respectively. The four point mutations are highlighted and denoted with the amino acid change. The Gly186Val mutation is located in the DFG motif (boxed) [@pone.0034838-Taylor1]. **B.** The location of the four mutations are indicated (red) in a model of Cα1 based on the PDB structure 3FJQ [@pone.0034838-Thompson1]. Residues are designated according to the WT Cα1 sequence. ATP and two divalent cations are shown in yellow. **C.** Immunoblotting and phosphotransferase assays of WT and mutated Cα1 subunits. Cα1 was expressed in HEK 293T cells and immunoreactive C subunit detected with anti-C (Anti-mouse PKA\[C\], cat. no. 610981) after separation of cell extracts by SDS-PAGE in 10% gels and immunoblotting. Expression of Cα1~WT~ is shown in lane 1 (WT), mutated Cα1 in lanes 2 to 5, and endogenous Cα1 in lane 6 (Mock). Activities are normalized relative to Cα1~WT~ activity. Data represents mean values ± standard deviation (SD) of triplicate experiments (\*, P \< 0.05. \*\*, P \< 0.005).](pone.0034838.g001){#pone-0034838-g001}

By the second approach, we detected another twelve nonsynonymous mutations ([Table 4](#pone-0034838-t004){ref-type="table"}), of which the majority has been submitted within the last year. Among the mutations that were known at the initiation of this study, two were selected for further investigations. Firstly, the mutation rs35635531, resulting in a switch of Ser~263~ to Cys, is the only mutation that has been submitted by three independent projects. Although the frequency of this mutation has not been determined in detail, it is likely to be relatively common in at least some human populations. Secondly, the mutation causing the Gly186Val mutation was considered particularly intriguing since this residue is located in the Mg^2+^ positioning loop close to ATP and Mg^2+^ in the active site cleft of Cα ([Fig. 1B](#pone-0034838-g001){ref-type="fig"}) and is part of the highly conserved DFG motif [@pone.0034838-Taylor1], [@pone.0034838-TenEyck1], [@pone.0034838-Kornev2]. The positions of the four investigated mutations resulting in amino acid switches are shown relative to exon encoded sequence in [Fig. 1A](#pone-0034838-g001){ref-type="fig"} and in the 3D structure of Cα1 in [Fig. 1B](#pone-0034838-g001){ref-type="fig"}.

10.1371/journal.pone.0034838.t004

###### Additional nonsynonymous mutations in the *PRKACA* gene found in public databases.

![](pone.0034838.t004){#pone-0034838-t004-4}

  dbSNP          Exon no.   Nucleotide no.   Amino acid        WT/mut nt        WT/mut aa                            Functional consequence prediction
  ------------- ---------- ---------------- ------------ --------------------- ----------- -------------------------------------------------------------------------------------
  rs142045517       2            103           Ala34              G/A            Ala/Thr    Ala34 is Ser in rodent Cα and Thr in human Cβ -- likely few functional consequences
  rs56029020        3            121           Leu40              T/G            Leu/Val      Leu40 is absolutely conserved in metazoan Cα/Cβ homologs -- likely deleterious
  rs112360106       3            149           Leu49              T/A            Leu/His                Conserved in metazoan Cα/Cβ homologs -- likely deleterious
  rs148280386       5            409           Gly136             G/A            Gly/Arg                Conserved in metazoan Cα/Cβ homologs -- likely deleterious
  rs142007512       6            541           Ile180             A/G            Ile/Val            Highly conserved in vertebrate Cα/Cβ -- possibly functional effects
  rs11541563        7            560           Gly186             G/T            Gly/Val                Conserved in metazoan Cα/Cβ homologs -- likely deleterious
  rs34988264        8            673           Leu224     -/G, 1 nt insertion                        Frame shift in exon 8 -- very likely results in nonfunctional Cα
  rs35635531        9            791           Ser263             C/G            Ser/Cys        Highly conserved in metazoan Cα/Cβ homologs -- possibly functional effects
  rs146946205       9            842           Arg280             G/A            Arg/His                Conserved in metazoan Cα/Cβ homologs -- likely deleterious
  rs187770246       9            926           Arg308             G/A            Arg/Lys               Conserved as Arg or Lys in metazoa -- likely few consequences
  rs149832080       10           955           Phe318             T/C            Phe/Leu                  Not conserved in vertebrates -- likely few consequences
  rs141087932       10           1045          Ser348             T/C            Ser/Pro                    Not conserved in mammals -- likely few consequences

Enumeration is given as in [Table 3](#pone-0034838-t003){ref-type="table"}, and sequence conservation is illustrated in Supplementary [Fig. S1](#pone.0034838.s001){ref-type="supplementary-material"}. Reference identifiers from dbSNP [@pone.0034838-Sherry1], [@pone.0034838-Sayers2] are included in the left column.

Mutation of Residues Ser~109~ and Gly~186~, but not Arg~45~ and Ser~263~ in Cα1 Influences Catalytic Activity {#s3a}
-------------------------------------------------------------------------------------------------------------

We first tested if any of the mutations influenced the catalytic activity of Cα. Site-directed mutagenesis was used to introduce the required amino acid switches Arg45Gln, Ser109Pro, Gly186Val, and Ser263Cys to Cα encoding expression vectors. Wild type (WT) and the four mutated Cα1 products (collectively termed Cα1~Mut~) were expressed in HEK-293T cells, and 20 h post transfection the cells were lysed. Expression of protein was first assessed by immunoblotting with a pan C antibody, revealing that both Cα1~WT~ ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}, lane 1) and Cα1~Mut~ ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}, lanes 2 to 5) were expressed at comparable levels and with similar apparent size as endogenous Cα1 ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}, lane 6). We further determined their catalytic activity in the presence of the PKA-specific substrate Kemptide and γ-^32^P-ATP ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}). In these experiments, lysates from untransfected cells ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}, lane 6) were included to assess endogenous kinase activity. This demonstrated high catalytic activity of expressed Cα1~WT~ which was set to 100% ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}, lane 1). According to this assay, the catalytic activities of Cα1~Arg45Gln~ and Cα1~Ser263Cys~ were shown not to be significantly different from Cα1~WT~. On the other hand, the activity of Cα1~Ser109Pro~ was significantly lower compared to Cα1~WT~ (P \<0.05), and the activity of Cα1~Gly186Val~ was comparable to background levels ([Fig. 1C](#pone-0034838-g001){ref-type="fig"}, lanes 4 and 6). This suggested that mutation of Gly~186~ rendered Cα inactive and prompted us to focus further on revealing the mechanism for this inactivation. Accordingly, we transfected cells with Cα1~Gly186Val~ and Cα1~WT~ and compared catalytic activity in the absence and presence of cAMP and the PKA-specific inhibitor PKI and compared phosphotransferase activities to mock transfected cells ([Fig. 2A](#pone-0034838-g002){ref-type="fig"}). The activity of Cα1~WT~ was reduced to background level in the presence of PKI while activities of Cα1~Gly186Val~ were comparable to background levels independently of stimulation with cAMP or inhibition with PKI ([Fig. 2A](#pone-0034838-g002){ref-type="fig"}, Mock compared to Cα1~Gly186Val~).

![Activity of wild type and Gly186Val mutated Cα1 and Cα2.\
**A.** Phosphotransferase activity of Cα1~WT~ and Cα1~Gly186Val~ expressed in HEK-293T cells was measured in the presence of Kemptide and γ-^32^P-ATP, and in the presence (+) and absence (−) of cAMP or PKI kinase inhibitor. Enzyme activity was normalized according to activity of Cα1~WT~ which was set to 100%. The data are presented as mean values ± SD of triplicate experiments. **B.** Recombinant Cα2~WT~ (not shown) and Cα2~Gly186Val~ were expressed in BL21 (DE3) cells. For Cα2~Gly186Val~, expressed protein was purified by running cell extracts over a Ni-resin loaded with His6RIIα~Gly337Glu~ affinity column and eluted with 10 mM cAMP. The purification steps of Cα2~Gly186Val~ are shown after separation of the various fractions by SDS-PAGE. The crude cell extract (lane 1, crude) was centrifuged and divided into a soluble (lane 2) and an insoluble fraction (lane 3, pellet). Proteins not retained on the column is shown (lane 5, Flowthrough). W1, W3, W4 and W5 (lanes 6 and 8--10) depict protein contents of successive washing steps using buffer containing 50 mM NaH~2~PO~4~ (pH 8.0), 5 mM β-mercaptoethanol, and 25 mM KCl. E1-E4 (lanes 11--14 ) depict protein content in consecutive elution fractions using buffer containing 50 mM NaH~2~PO~4~ (pH 8,0), 10 mM cAMP, 5 mM β-mercaptoethanol, and 25 mM KCl. To assure equal amounts of RIIα~Gly337Glu~ and Cα2~Gly186Val~, cell extracts of RIIα~Gly337Glu~ and Cα2~Gly186Val~ expressed in separate bacteria cultures were mixed 1∶1 (lane 7, 1∶1 mix). Protein with the correct molecular mass (arrow to the right) was obtained in fractions E1--E3. Ten µl was applied in lanes 6, 8, 9 and 10, seven µl in lane 1, 2, 3, 5 and 7, and five µl in lane 4. (Molecular Weight Marker (MWM)). **C.** Kinase activity of recombinant Cα2~WT~ and Cα2~Gly186Val~ was determined by employing the spectrophotometric Cook assay. The data are presented as mean values ± SD of triplicate experiments.](pone.0034838.g002){#pone-0034838-g002}

To determine if Cα~Gly186Val~ was completely inactive we next expressed and purified recombinant Cα~WT~ and Cα~Gly186Val~. We used recombinant WT and mutated Cα2 since Cα2 is more easily produced than Cα1 due to higher solubility [@pone.0034838-Vetter1]. Cα2 will therefore give a higher protein yield. Cα1 and Cα2 may also be interchanged in these experiments because studies suggest that they are kinetically indistinguishable [@pone.0034838-Vetter1]. WT and mutated recombinant Cα2 (Cα2~WT~ and Cα2~Gly186Val~) were produced in BL21(DE3) cells, purified and visualized by SDS-PAGE ([Fig. 2B](#pone-0034838-g002){ref-type="fig"}). (In order to simplify the nomenclature we refer to the mutations according to their Cα1 numbering also when introduced to Cα2. The actual position of the mutated residues in the Cα2 protein is achieved by subtracting the number 8). Cα2~Gly186Val~ was purified by running protein extracts over an RIIα~Gly337Glu~ affinity column and Cα2 bound to RIIα was eluted with 10 mM cAMP (see [Material and Methods](#s2){ref-type="sec"}). The purification process was evaluated after each step by SDS-PAGE analysis ([Fig. 2B](#pone-0034838-g002){ref-type="fig"}, lanes 1 to 14). Purified Cα2~Gly186Val~ and Cα2~WT~ were tested for catalytic activity employing the Cook assay [@pone.0034838-Cook1] that showed a specific activity for Cα2~WT~ at 20.9 ± 2.1 U/mg (95% confidence interval) ([Fig. 2C](#pone-0034838-g002){ref-type="fig"}, Cα2~WT~). In comparison, catalytic activity by Cα2~Gly186Val~ was undetectable demonstrating that a Gly~186~ to Val mutation renders the kinase catalytically inactive (95% confidence interval of Cα2~Gly186Val~: 0.55 ± 0.96 U/mg) ([Fig. 2C](#pone-0034838-g002){ref-type="fig"}, Cα2~Gly186Val~).

Mutation Gly186Val Alters the Catalytic Core of Cα1 {#s3b}
---------------------------------------------------

We next investigated the Gly186Val mutation in a 3D structure model of Cα1 in an attempt to understand the molecular nature of the kinetic inactivity ([Fig. 3](#pone-0034838-g003){ref-type="fig"}). [Figure 3A](#pone-0034838-g003){ref-type="fig"} shows selected conserved motifs surrounding the DFG motif where residue 186 is located. The chain of interactions leading into the DFG motif from phosphorylated Thr~197~ is depicted. In the active conformation of Cα1~WT~, the C- and R-spines are assembled and the structure is optimized for catalysis ([Fig. 3B](#pone-0034838-g003){ref-type="fig"}). Simulated mutagenesis of Gly186Val revealed three possible rotamers. For representation in the figures, the rotamer with the least steric hindrance was selected. Our Cα1~Gly186Val~ model suggests an altered conformation of the DFG motif, which we hypothesize may disturb the structure of the spines ([Fig. 3B](#pone-0034838-g003){ref-type="fig"}, lower right box). In all published experimental structures of catalytically active kinases, there is a conserved hydrogen bond between the side chain of Asp~184~ and the amide group of Gly~186~ [@pone.0034838-TenEyck1] ([Fig. 3C, left panel](#pone-0034838-g003){ref-type="fig"}, dashed line). In [figure 3C](#pone-0034838-g003){ref-type="fig"} (right panel) it is shown that the presence of the hydrophobic Val side chain leads to steric hindrance and an unfavourable binding of the cation Mn1 (Cγ1-Mn1 distance 2.7 Å) compared to Gly (Cα-Mn1 distance 4.3 Å). The simulated distances between Cγ1, Cγ2 and Mn1 as well as ATP for this rotamer and the two other rotamers of Cα1~Gly186Val~ were reduced (results not shown). According to these data we hypothesize that by replacing Gly~186~ with Val, the bulky side chain of Val will make it less likely for Cα to bind Mg1/Mn1 in its optimal position. This will also prevent ATP binding, together suggesting why Cα2~Gly186Val~ lacks kinase activity.

![Mutation of Gly186 in Cα1 prevents Cα from binding ATP and divalent cations.\
**A.** The 3D structure of the catalytic site of Cα1. Selected conserved motifs and their relations to divalent cations Mn1 and Mn2 and ATP are shown. Residues connecting phospho-Thr~197~ (pThr~197~) to the DFG motif are represented as stick models [@pone.0034838-TenEyck1]. Mn~2~ATP (green), the DFG motif (teal), Gly-rich loop (salmon), catalytic loop (yellow), and activation loop (purple) are also highlighted. **B.** Overall structure of Cα1~WT~ with the conserved structural motifs the C- and R-spine structural motifs highlighted. The boxed segments depict spatial relations between residue 186 (Gly or Val) and ATP, divalent cations, and the C- and R-spines. **C.** DFG motif in Cα1~WT~ (left) and Cα1~Gly186Val~ (right) and its relations to Mn1 and ATP. Residues are represented as stick models with carbon (orange), oxygen (red) and nitrogen (blue) atoms. The hydrogen bond between the side chain of Asp~184~ and the amide group of Gly~186~ (dashed line) is predicted to be broken in Cα1~Gly186Val~ due to the Val side chain. The models are based on the structure with PDB identifier 3FJQ [@pone.0034838-Thompson1].](pone.0034838.g003){#pone-0034838-g003}

A recent study on the Raf kinase where Gly~596~, which is the counterpart of Gly~186~ in Cα1, was mutated to Arg revealed that some Raf~Gly569Arg~ kinase activity was achieved at high concentrations of ATP [@pone.0034838-Moretti1]. Based on this study and considering the molecular structure depicted in [figure 3](#pone-0034838-g003){ref-type="fig"} we speculated if increasing the concentrations of ATP and/or Mg^2+^ would be sufficient to restore at least some kinase activity in Cα2~Gly186Val~. Kinase activity of purified Cα2~Gly186Val~ and Cα1~WT~ were measured against increasing doses of Mg^2+^ and ATP, keeping either the ATP or Mg^2+^ concentration constant at 143 µM or 14.3 mM, respectively. For Cα1~WT~ high phosphotransferase activity was detected at concentrations of Mg^2+^ between 0.2 and 100 mM and ATP-concentrations between 1 and 143 µM. At none of these concentrations was activity of Cα2~Gly186Val~ detectable.

Cα2~Gly186Val~ Associates with RIIa but not RIa {#s3c}
-----------------------------------------------

Cα2~Gly186Val~ was purified by affinity chromatography with RIIα in which Cα~Gly186Val~ was released by addition of cAMP. This suggests that mutation of Cα1 at residue 186 does not interfere with RII association or cAMP activation. However, ATP is required for association between C and RI [@pone.0034838-Herberg1], [@pone.0034838-Herberg2] and given the fact that Cα2~Gly186Val~ probably does not bind ATP efficiently, it may be suggested that Cα~Gly186Val~ will only associate with RII and not RI. To investigate this we determined the binding of Cα1~Gly186Val~ to RIα and RIIα using a Bioluminescence resonance energy transfer (BRET) assay. In these experiments, holoenzyme formation was investigated for all four Cα~Mut~ proteins to test if any of the mutations would influence R subunit binding and cAMP sensitivity. COS-7 cells were cotransfected with either Cα1~WT~ or Cα1~Mut~ N-terminally coupled to Green Fluorescent Protein (GFP), GFP-Cα1~WT~ and GFP-Cα1~Mut~, respectively, and RIα and RIIα C-terminally coupled to *Renilla* luciferase (Rluc),RIα-Rluc and RIIα-Rluc, respectively. Immunoblotting shows the expression of both GFP-Cα1~WT~ and GFP-Cα1~Mut~ ([Fig. 4A](#pone-0034838-g004){ref-type="fig"}, lanes 2 to 6). [Figure 4](#pone-0034838-g004){ref-type="fig"}, lane 1 depicts the expression of endogenous C subunit in cells transfected with Rluc alone serving as background. In the case of holoenzyme formation with RIα subunits, measurements were normalized by setting the BRET signal in holoenzyme with GFP-Cα1~WT~ to 100% ([Fig. 4B](#pone-0034838-g004){ref-type="fig"}, WT "−\"). Increasing the intracellular concentration of cAMP with forskolin (fsk) and IBMX ("+\") leads to the dissociation of the holoenzyme complex and the reduction of the BRET signal by approximately 50% as reported previously [@pone.0034838-Diskar1]. The same was true for holoenzymes formed with RIα-Rluc and GFP-Cα1~Arg45Gln~, GFP-Cα1~Ser109Pro~, and GFP-Cα1~Ser263Cys~, respectively ([Fig. 4B](#pone-0034838-g004){ref-type="fig"}, "+\"). In contrast, the GFP-Cα1~Gly186Val~ showed only residual binding to RIα in resting cells ([Fig. 4B](#pone-0034838-g004){ref-type="fig"}, Gly186Val "−\"), and only marginal activation was detected after stimulation with fsk and IBMX ([Fig. 4B](#pone-0034838-g004){ref-type="fig"}, Gly186Val "+\").

Analogous to RIα-Rluc measurements with RIIα-Rluc were performed setting unstimulated WT holoenzyme to 100% ([Fig. 4C](#pone-0034838-g004){ref-type="fig"}, WT "−\"). PKA type II holoenzymes formed with GFP-Cα~WT~ and GFP-Cα~Mut~ dissociate almost completely resulting in a stronger BRET signal reduction ([Fig. 4C](#pone-0034838-g004){ref-type="fig"}, "+\"). Interestingly, whereas GFP-Cα1~Gly186Val~ does not stably interact with RIα-Rluc, the holoenzymes formed with RIIα-Rluc shows a comparable magnitude to GFP-Cα1~WT~ ([Fig. 4C](#pone-0034838-g004){ref-type="fig"}, Gly186Val "−\" and WT "−\").

![Assessment of PKA type I and II holoenzyme formation and dissociation with Cα~WT~ and Cα~Mut~ applying BRET in living cells.\
Co-expression of GFP-Cα1~WT~ or GFP-Cα1~Mut~ with wt RIα and RIIα subunits fused to *Renilla* luciferase (RIα-Rluc, RIIα-Rluc, as described in Diskar et al [@pone.0034838-Diskar1] and [Material and Methods](#s2){ref-type="sec"}). **A.** Western blot analysis of COS-7 cells expressing either *Renilla* luciferase alone (lane 1), or R-Rluc plus GFP-Cα1~WT~ (lane 6) and GFP-Cα1~Mut~ (lanes 2--5). Molecular mass and C subunit identity is shown at the left and right, respectively. **B.** Analysis of PKA type I holoenzyme formation (RIα-Rluc) with GFP-Cα1~WT~ or GFP-Cα1~Mut~. Expression of Rluc alone defines the background signal (lane 1). 48 h post transfection the luciferase substrate was added and light emission from GFP^2^ and luciferase was monitored in the absence (−) or presence (+) of 50 µM forskolin (fsk) and 100 µM IBMX (+). The results are shown as mean values ± SEM of 3 experiments. C. Analysis of PKA type II holoenzyme formation (RIIα-Rluc) was done as described for PKA type I in panel B.](pone.0034838.g004){#pone-0034838-g004}

Discussion {#s4}
==========

Here we have examined the human *PRKACA* gene for mutations by sequencing genomic DNA from 498 Norwegian individuals and by searching for earlier reported mutations in publicly available databases. By genomic sequencing, we identified two nucleotide changes that resulted in the mutations Arg45Gln and Ser109Pro in the Cα1 protein. In public databases we identified two interesting mutations that would lead to residue switches, Gly186Val and Ser263Cys.

Two out of the four mutations (Cα1~Ser109Pro~ and Cα1~Gly186Val~) resulted in significantly reduced kinase activity. It should, however, be noted that comparing the exact activities of Cα1~WT~ and Cα1~Mut~ was a challenge due to differences in transfection efficiencies. We compensated for this by adjusting activities to immunoreactivity in the immunoblots. This demonstrated reduced kinase activity for Cα1~Ser109Pro~, whereas Cα1~Gly186Val~ was kinase inactive. As Gly~186~ is absolutely conserved (Supplementary [Fig. S1](#pone.0034838.s001){ref-type="supplementary-material"}) and is part of the DFG motif [@pone.0034838-Kornev1] we investigated the mutation affecting this residue in more detail. The importance of Gly~186~ conservation was underscored since mutation was associated with complete abrogation of kinase activity. The exact mechanism that leads to complete inactivation in this case is not known. However, Cα~Gly186Val~ was successfully purified by RIIα-affinity chromatography followed by elution with cAMP. This, together with the fact that Cα~Gly186Val~ forms cAMP-sensitive holoenzymes with RIIα *in vivo* suggests that lack of enzymatic activity is not caused by an overall misfolding of the protein. We rather suggest that lack of kinase activity is due to less extensive molecular changes, affecting only parts of the protein structure. The introduction of a bulky residue in place of Gly~186~ is likely to affect many critical factors necessary for kinase activity. The most apparent explanation is that the aliphatic Val~186~ side chain leads to less efficient binding of Mg1/Mn1 due to displacement of the cation itself or water molecules that are solvating Mg1/Mn1. Loss of Mg1/Mn1 would in turn disable ATP binding, thus explaining the kinase inactivity. This hypothesis is supported by our BRET results, which show exclusive binding to RII but not RI subunits. Moreover, we were unable to purify Cα~Gly186Val~ using PKI affinity chromatography (results not shown). It has previously been shown that the RI subunits, as well as PKI, need ATP to bind C with high affinity [@pone.0034838-Herberg1], [@pone.0034838-Herberg2].

According to our model, it is not unlikely that the hydrogen bond between residues 184 and 186 fails to form in Cα~Gly186Val~, leading to displacement of Asp~184~ and inability to position Mg1 or Mn1 and thereby ATP in the active site. The inability to bind ATP implicates that the C-spine is not established, which is necessary for the active conformation. An alternative explanation for the inactivity is that Val~186~, instead of suppressing binding of Mg1/Mn1 and ATP, is rather displaced, leading to a conformational change in the DFG motif itself. This would lead to a malformed R-spine, which is also thought to be incompatible with kinase activity [@pone.0034838-Taylor1].

Reduced kinase activity was also observed for Cα1~Ser109Pro~. Ser~109~ is located in the middle of β-strand 4 in the small lobe and this β-strand stabilizes the N-terminal end through targeting Ser~109~ to Thr~37~ [@pone.0034838-Thompson1]. It is well known that the N-terminal tail is important for C subunit stability, and deletion of the N-terminus has previously been demonstrated to lead to a significant reduction in thermal stability [@pone.0034838-Herberg3]. We speculate that mutation of Ser~109~ to Pro leads to partial loss of N terminal structure and destabilization of the kinase, and that this may in part provide an explanation for the reduced kinase activity. A second consequence of mutating Ser~109~ may be associated with our recent findings that Ser~109~ belongs to a series of signature residues that can be used to distinguish the Cα from Cβ ortholog (unpublished results). Due to this, the Ser109Pro mutation may result in alteration of Cα-specific functions which do not include holoenzyme formation since our BRET-results showed that Cα1~Ser109Pro~ formed holoenzymes with both RIα and RIIα with comparable affinities as the Cα1~WT~. Full comprehension of the reduced kinase activity and other features associated with mutation at Ser~109~ merits further investigation.

Neither mutations of Arg45Gln nor Ser263Cys influenced apparent kinase activity. Arg~45~ is located near a recently identified conserved pocket in the N lobe known as the N lobe cap, which is above the crucial amino acids Ala~70~ and Lys~72~ [@pone.0034838-Thompson1]. Ala~70~ is part of the C-spine while Lys~72~ is directly involved in ATP binding. It might have been expected that mutation of Arg~45~ would affect kinase activity, also because this residue is highly conserved in metazoan PKA Cα/Cβ homologs (Supplementary [Fig. S1](#pone.0034838.s001){ref-type="supplementary-material"}) and is clearly under strong purifying selection. The fact that we did not observe any change in phosphotransferase activity suggests that the mutation does not influence the positioning of Ala~70~ and Lys~72~. Despite of this, it may be that mutation of residue 45 affects other features necessary for function of the kinase. It could be speculated that the N lobe cap may also be a docking site for proteins inhibiting kinase activity by disturbing either the C-spine or Lys~72~. This may indicate that the Arg45Gln mutation could be involved in deregulated PKA activity due to altered interactions with so far unidentified interaction partners docking to the N lobe cap. This binding partner does not include the R subunit since the BRET experiments of Cα1~Arg45Gln~ showed no differences in binding and release upon fsk/IBMX stimulation of RIα and RIIα subunits compared to Cα1~WT~. This is also consistent with the localization of Arg~45~ far from the R subunit docking site.

Ser~263~ is highly conserved among metazoa (Supplementary [Fig. S1](#pone.0034838.s001){ref-type="supplementary-material"}) and is part of the H helix at the very lower end of the large lobe. This site is close to the R subunit docking sites, and the mutation would not be expected to interfere directly with catalytic activity as was also demonstrated here. Rather it could be speculated that a shift from Ser to Cys could influence the mechanism regulating R-C interaction *in vivo*. However, our BRET experiments showed no difference in holoenzyme formation and dissociation of Cα1~Ser263Cys~ to neither RIα nor RIIα subunits compared to Cα1~WT~. Although no effect of a Ser263Cys mutation in Cα was detected, the high degree of conservation of this residue and strong purifying selection is an indicator of a hereto unknown functional importance of Ser~263~.

Among the mutations identified in the sequencing of the *PRKACA* gene, Arg45Gln and Ser109Pro were identified in one and two samples, respectively. Of the two mutations identified in the database search only the Ser263Cys mutation was identified by two independent submitters. To what extent this indicates anything about the prevalence of the different mutations, remains to be verified. However, Gly in the DFG motif is a relatively frequent site of disease-causing mutation in various protein kinases which is most likely due to kinase inactivation [@pone.0034838-Torkamani1]. As described above, homozygote targeting mutation of the *PRKACA* gene in mouse is associated with high pre- and postnatal lethality, most probably due to lack of kinase activity at critical steps in embryonic development [@pone.0034838-Skalhegg2], [@pone.0034838-Nolan1]. Based on this, it is expected that any mutation affecting Cα activity may lead to a severe phenotype and possibly disease in human. Since the Cα1~Gly186Val~ mutation resulted in catalytic inactivation and partial lack of holoenzyme formation, homozygote mutation for Gly~186~ *in vivo* may functionally be considered a gene KO and hence may be incompatible with normal development and life. The same would most likely be the case for the frame shift mutation detected in exon 8. The fact that Cα~Gly186Val~ exclusively forms holoenzyme with RII subunits suggest that individuals with heterozygote mutation of Gly~186~ may have reduced levels of PKA type I holoenzymes, in addition to harboring type II holoenzymes occupied by inactive C subunits, which can hypothetically cause an unbalance in PKA signaling.

The other investigated mutations are likely more compatible with normal development and may not be associated with disease since neither of them influenced holoenzyme formation and mutation of Ser~109~ only partly reduced catalytic activity. Despite this there is a possibility that homozygote mutation of Ser~109~ may be associated with disease since experiments on mice have demonstrated that reduced C subunit gene expression can lead to spinal neural tube defects [@pone.0034838-Huang1]. In total, 13 nonsynonymous point mutations in the *PRKACA* gene were identified in the present study. For example the Gly186Val mutation was only identified in a single EST sequence, and no frequency data was available. Hence, the information on the prevalence of the various mutations is therefore limited and a full comprehension of their existence in patients or patient groups remains to be elucidated. Finally, it is also worth mentioning that several thousand regions of the human genome have structural variation in large segments termed Copy Number Variation (CNV) [@pone.0034838-Wong1]. In this paper they report that three out of 95 individuals were found to have a loss of ∼160 kb which included the whole *PRKACA* gene as well as up- and downstream genes. Due to this it may be speculated that a combination of CNV deletion at the *PRKACA* locus and a heterozygote loss-of-function mutation of Cα could be associated with disease due to severe reduction in C subunit gene dose. To what extent this is a cause of disease remains to be determined.
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Multiple sequence alignment of human PKA Cα (top row) and homologous sequences from a number of metazoan species for the sequence segments containing the 13 mutations discussed in the present study. Enumeration is according to the human PKA Cα1 splice variant and the mutated residues are highlighted. The sequences were obtained from the NCBI (<http://www.ncbi.nlm.nih.gov>) and UniProt (<http://www.uniprot.org>) protein sequence databases with the following identifiers: P17612, P05132, P00517, NP_001003032, Q90WN3, A3KMS9, NP_001003470, P22694, P68181, P05131, XP_867543, XP_422379, Q7ZWV0, Q3ZB92, Q7T374, XP_001175934, XP_002740161, CAG44453, XP_393285, XP_968170, NP_476977.
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